| Literature DB >> 29569506 |
Wenming Zhang1, Chunrong Lin1, Vanitha Sampath1, Kari Nadeau1.
Abstract
Although traditional pharmacological approaches improve outcomes in disease management for allergic asthma, these fail to modify the underlying immune responses. Allergen immunotherapy remains the only etiological therapy for the treatment of respiratory allergies for which clinical efficacy has been demonstrated through several well-controlled studies. In this review, we examine evidence from the past 5 years regarding the impact of allergen immunotherapy on allergic asthma to inform practitioners and stimulate further discussion and research.Entities:
Keywords: allergen immunotherapy (AIT); allergic asthma; mechanisms; omalizumab; subcutaneous immunotherapy (SCIT); sublingual immunotherapy (SLIT)
Mesh:
Substances:
Year: 2018 PMID: 29569506 PMCID: PMC5994829 DOI: 10.2217/imt-2017-0138
Source DB: PubMed Journal: Immunotherapy ISSN: 1750-743X Impact factor: 4.196